Skye Bioscience to Conduct Meetings at Piper Sandler Conference
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company specializing in obesity and metabolic health disorders treatments, has announced that its executive team will be participating in the Piper Sandler Spring Biopharma Symposium. The event is scheduled for April 17th, 2025, in Boston, MA, where the company will be available for one-on-one meetings.
Skye Bioscience (Nasdaq: SKYE), un'azienda biofarmaceutica in fase clinica specializzata nel trattamento dell'obesità e dei disturbi della salute metabolica, ha annunciato che il suo team esecutivo parteciperà al Piper Sandler Spring Biopharma Symposium. L'evento è programmato per il 17 aprile 2025 a Boston, MA, dove l'azienda sarà disponibile per incontri individuali.
Skye Bioscience (Nasdaq: SKYE), una empresa biofarmacéutica en fase clínica especializada en el tratamiento de la obesidad y trastornos de salud metabólica, ha anunciado que su equipo ejecutivo participará en el Piper Sandler Spring Biopharma Symposium. El evento está programado para el 17 de abril de 2025 en Boston, MA, donde la empresa estará disponible para reuniones individuales.
Skye Bioscience (Nasdaq: SKYE)는 비만 및 대사 건강 장애 치료를 전문으로 하는 임상 단계의 생명공학 회사로, Piper Sandler Spring Biopharma Symposium에 경영진 팀이 참여할 것이라고 발표했습니다. 이 행사는 2025년 4월 17일 매사추세츠주 보스턴에서 예정되어 있으며, 회사는 일대일 미팅을 위해 참석할 예정입니다.
Skye Bioscience (Nasdaq: SKYE), une entreprise biopharmaceutique en phase clinique spécialisée dans le traitement de l'obésité et des troubles de la santé métabolique, a annoncé que son équipe dirigeante participera au Piper Sandler Spring Biopharma Symposium. L'événement est prévu pour le 17 avril 2025 à Boston, MA, où l'entreprise sera disponible pour des réunions individuelles.
Skye Bioscience (Nasdaq: SKYE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von Fettleibigkeit und Stoffwechselerkrankungen spezialisiert hat, hat bekannt gegeben, dass sein Führungsteam am Piper Sandler Spring Biopharma Symposium teilnehmen wird. Die Veranstaltung ist für den 17. April 2025 in Boston, MA, geplant, wo das Unternehmen für Einzelgespräche zur Verfügung stehen wird.
- None.
- None.
SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that its executive team will be available for 1x1 meetings at the Piper Sandler Spring Biopharma Symposium on April 17th in Boston, MA.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
When is Skye Bioscience (SKYE) attending the Piper Sandler Spring Biopharma Symposium?
What type of meetings will SKYE executives conduct at the Piper Sandler conference?
What is Skye Bioscience's (SKYE) current development stage and therapeutic focus?
Which stock exchange is Skye Bioscience (SKYE) listed on?
